Skip to main content
SpringerLink
Log in

Efficacy of dulaglutide after switching from incretin-related drugs in patients with type 2 diabetes and inadequate glycemic control

  • Original Article
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

Aims

The efficacy of dulaglutide was assessed according to the pretreatments administered before the initiation of dulaglutide in patients with type 2 diabetes.

Methods

In total, 89 patients treated using dulaglutide (0.75 mg, once a weekly) were investigated. The subjects were divided into the three groups based on the form in which therapy was started: additional therapy (n = 35), switched from dipeptidyl peptidase-4 (DPP-4) inhibitors (n = 32) and switched from daily glucagon-like peptide-1 receptor agonists (GLP-1 RAs, n = 30). The changes in medication adherence were determined in the daily GLP-1 RAs group using questionnaire surveys.

Results

The HbA1c values significantly decreased after the initiation of dulaglutide in all groups (additional therapy group, − 1.4 ± 1.6%; DPP-4 inhibitors group, − 1.2 ± 1.3%; and daily GLP-1 RAs group, − 0.5 ± 0.7%). Forty-six percent of the subjects in the daily GLP-1 RAs group reported that the incidence of forgetting injections of GLP-1 RA was decreased. The reduction of HbA1c was significantly greater in the subjects who reported a decrease in the incidence of forgetting injections (0.9 ± 0.9%) in comparison to those in which there was no change (0.1 ± 0.4%).

Conclusions

Dulaglutide is considered effective in patients with type 2 diabetes and inadequate glycemic control, regardless of whether their pretreatment includes daily GLP-1 RA treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kohro T, Yamazaki T, Sato H, Harada K, Ohe K, Komuro I, Nagai R. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011. Int Heart J. 2013;54:93–7.

    Article  Google Scholar 

  2. Nishio S, Abe M, Ito H. Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. Diabetes Metab Syndr Obes. 2015;8:163–71.

    PubMed  PubMed Central  Google Scholar 

  3. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes -2018. Diabetes Care. 2018; 41: S73–85.

  4. Ito H, Ando S, Tsugami E, Araki R, Kusano E, Matsumoto S, Uemura K, Nishio S, Antoku S, Yamasaki T, Mori T, Togane M. Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes. Diabetes Res Clin Pract. 2019;153:41–8.

    Article  CAS  Google Scholar 

  5. Alatorre C, Fernández Landó L, Yu M, Brown K, Montejano L, Juneau P, Mody R, Swindle R. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide. Diabetes Obes Metab. 2017;19:953–61.

    Article  CAS  Google Scholar 

  6. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 982–92.

  7. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes -2021. Diabetes Care. 2021; 44: S111–24.

  8. Usui R, Yabe D, Kuwata H, Fujiwara S, Watanabe K, Hyo T, Yasuhara A, Iwasaki M, Kitatani N, Kuwabara K, Yokota K, Kurose T, Seino Y. Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function. J Diabetes Investig. 2013;4:585–94.

    Article  CAS  Google Scholar 

  9. Abd El Aziz MS, Kahle M, Meier JJ, Nauck MA. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab. 2017; 19: 216–27.

  10. Huthmacher JA, Meier JJ, Nauck MA. Efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists on a background of basal insulin in type 2 diabetes: a meta-analysis. Diabetes Care. 2020;43:2303–12.

    Article  CAS  Google Scholar 

  11. Emoto M, Terauchi Y, Ozeki A, Oura T, Takeuchi M, Imaoka T. A 1-year safety study of dulaglutide in Japanese patients with type 2 diabetes on a single oral hypoglycemic agent: an open-label, nonrandomized, phase 3 trial. Endocr J. 2015;62:1101–14.

    Article  CAS  Google Scholar 

  12. Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, Imaoka T. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes Obes Metab. 2015;17:994–1002.

    Article  CAS  Google Scholar 

  13. Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015;17:974–83.

    Article  CAS  Google Scholar 

  14. Odawara M, Miyagawa J, Iwamoto N, Takita Y, Imaoka T, Takamura T. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study. Diabetes Obes Metab. 2016;18:249–57.

    Article  CAS  Google Scholar 

  15. Takeshita Y, Takamura T, Kita Y, Otoda T, Kato K, Wakakuri H, Yamada M, Misu H, Matsushima Y, Kaneko S; Establishment of Rationale for Antiaging Diabetic Medicine (ERA-DM) Study Chapter 2 Group. Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: a randomized, parallel-group study. J Diabetes Investig. 2015; 6: 192–200.

  16. Miyagi M, Uchino H, Kumashiro N, Higa M, Shin K, Sasamoto M, Kitazato H, Tamaki M, Matsuhisa M, Hirose T. Up-titration strategy after DPP-4 inhibitor-based oral therapy for type 2 diabetes: a randomized controlled trial shifting to a single-dose GLP-1 enhancer versus adding a variable basal insulin algorithm. Diabetes Ther. 2018;9:1959–68.

    Article  CAS  Google Scholar 

  17. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19:524–36.

    Article  CAS  Google Scholar 

  18. Ishigaki Y, Strizek A, Aranishi T, Arai N, Imaoka T, Cai Z, Maegawa H. Glucagon-like peptide-1 receptor agonist utilization in type 2 diabetes in Japan: a retrospective database analysis (JDDM 57). Diabetes Ther. 2021;12:345–61.

    Article  CAS  Google Scholar 

  19. Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A; SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018; 6: 275–86.

  20. Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergès B, Marre M. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020; 46:100–9.

  21. Cai X, Ji L, Chen Y, Yang W, Zhou L, Han X, Zhang S, Ji L. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: a meta-analysis. J Diabetes Investig. 2017;8:510–7.

    Article  CAS  Google Scholar 

  22. Zhang P, Zhang H, Li X, Chen M, Wang D, Ji L. Factors and outcomes associated with discontinuation of basal insulin therapy in patients with type 2 diabetes mellitus. Endocrinol Diabetes Metab. 2020;3:e00122.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Yavuz DG, Ozcan S, Deyneli O. Adherence to insulin treatment in insulin-naïve type 2 diabetic patients initiated on different insulin regimens. Patient Prefer Adherence. 2015;9:1225–31.

    Article  Google Scholar 

  24. Kirkman MS, Rowan-Martin MT, Levin R, Fonseca VA, Schmittdiel JA, Herman WH, Aubert RE. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015;38:604–9.

    PubMed  PubMed Central  Google Scholar 

  25. Ando S, Ito H, Tanaka M, Tsugami E, Araki R, Matsumoto S, Nishio S, Abe M, Antoku S, Mifune M, Togane M. The current status and background factors of unused drugs in patients with type 2 diabetes: a cross-sectional study using a questionnaire survey. Journal of the Japan Diabetes Society. 2018; 61: 375–81 (in Japanese, Abstract in English).

  26. Tanaka M, Ito H, Nemoto A, Ikeda N, Omoto T, Shinozaki M, Nishio S, Abe M, Antoku S, Mifune M, Togane M. Relationship between the history of intermittent treatment for type 2 diabetes mellitus and the risk of diabetic vascular complications. Journal of the Japan Diabetes Society. 2015; 58: 100–8 (in Japanese, Abstract in English).

  27. Japan Diabetes Clinical Data Management Study Group. Mean BMI in each year. http://jddm.jp/data/index-2019/. Accessed 14 March 2021.

  28. Ito H, Antoku S, Izutsu T, Kusano E, Matsumoto S, Yamasaki T, Mori T, Togane M. The prognosis of subjects showing a reduced estimated glomerular filtration rate without albuminuria in Japanese patients with type 2 diabetes: a cohort study for diabetic kidney disease. Clin Exp Nephrol. 24: 1033–43.

  29. Ito H, Omoto T, Abe M, Matsumoto S, Shinozaki M, Nishio S, Antoku S, Mifune M, Togane M. Relationships between the duration of illness and the current status of diabetes in elderly patients with type 2 diabetes mellitus. Geriatr Gerontol Int. 2017;17:24–30.

    Article  Google Scholar 

  30. Gallwitz B, Dagogo-Jack S, Thieu V, Garcia-Perez LE, Pavo I, Yu M, Robertson KE, Zhang N, Giorgino F. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obes Metab. 2018;20:409–18.

    Article  CAS  Google Scholar 

  31. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, Magid DJ. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1836–41.

    Article  Google Scholar 

Download references

Acknowledgment

The authors thank Tomoko Koyanagi in the secretarial section and Mahika Tanaka in the department of nursing of Edogawa Hospital for their valuable help with data collection.

Funding

No funds were received in support of this work.

Author information

Authors and Affiliations

  1. Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital, 2-24-18Edogawa-ku, HigashikoiwaTokyo, 133-0052, Japan

    Hiroyuki Ito, Suzuko Matsumoto, Takuma Izutsu, Eiji Kusano, Jiro Kondo, Hideyuki Inoue, Shinichi Antoku, Tomoko Yamasaki, Toshiko Mori & Michiko Togane

  2. Department of Pharmacy, Edogawa Hospital, Tokyo, Japan

    Rie Araki

Authors
  1. Hiroyuki Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rie Araki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Suzuko Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takuma Izutsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eiji Kusano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jiro Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hideyuki Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shinichi Antoku
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tomoko Yamasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Toshiko Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Michiko Togane
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

H Ito contributed to conception, design, analysis, interpretation, writing first draft, editing, and final approval. R Araki contributed conception, interpretation, data collection and final approval. S Matsumoto, T Izutsu, E Kusano, J Kondo, H Inoue, S Antoku, T Yamasaki, T Mori and M Togane contributed to data collection and final approval.

Corresponding author

Correspondence to Hiroyuki Ito.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ito, H., Araki, R., Matsumoto, S. et al. Efficacy of dulaglutide after switching from incretin-related drugs in patients with type 2 diabetes and inadequate glycemic control. Diabetol Int 13, 91–100 (2022). https://doi.org/10.1007/s13340-021-00508-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-021-00508-3

Keywords

Search

Navigation